Single, multicenter Phase 3 imaging trial of approximately 280 patients with brain metastases designed to demonstrate sensitivity and specificity ...

VANCOUVER, BC / ACCESS Newswire / November 3, 2026 / (TSXV:TTG)(OTCQB:TTGXF) ("Trans Canada" or the "Company"), is pleased to announce that the Company has successfully completed its most recent ...

The duration of short ångström-wavelength X-ray pulses, which lasted merely 170 attoseconds, has finally been measured ...

Alterity has FDA agreement on ATH434’s pivotal trial design, while Recce has revised its Australian study and signed an ...

Data shows positive one-year safety and efficacy data from three patients enrolled in ongoing Phase 2 clinical trial being led by researchers at the National Institute of Allergy and Infectious ...

Data shows positive one-year safety and efficacy data from three patients enrolled in ongoing Phase 2 clinical trial being led by researchers at ...

The disease is thought to be divided into two subtypes, depending on where it originates in the body — the gut or the brain.

First-ever comprehensive presentation of DT120 clinical program to date including positive topline data from Panorama, Emerge ...

Researchers demonstrate a new Quantum Phase in RLC circuits, realizing loss-induced quadrupole topology from a gapped trivial ...

President Lee Jae Myung ordered accurate delivery of real estate statistics during a Cabinet meeting on November 3, noting ...

At the Dixie Vein, hole 3TS-26-41 tested for vein continuity approximately 30m below the intersection in the Dixie "Discovery Hole" (3TS-26-29), returning 8.52 m grading 1.84 g/t gold and 24.53 g/t ...

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today reported third quarter 2026 financial results and preliminary data from its multiple-ascending dose (MAD) clinical study for its potential best ...